Location Swansea, Swansea, United Kingdom Regions Europe, Middle East, and Africa (EMEA) Gender Male
Investor Type
LinkedIn View on LinkedIn
Bart started his career in 1990 with ABN AMRO Bank, where he enjoyed an international career in commercial banking. In 1997 he joined the ABN AMRO Private Equity department where he led the first investments in life sciences. Subsequently he set up the ABN AMRO Life Sciences Team. He headed this team from 2000 till 2006 when it spun out forming
Forbion Capital Partners. Bart has broad managerial and commercial expertise based on his vast experience in the sector. Currently Bart holds board seats at AM Pharma, Cytheris and Cellnovo. Earlier, Bart was on the Board of a number of very successful companies like Rhein Biotech (IPO 1999) and Ubisys, an antibody company that later merged with Introgene into Crucell (IPO 2000). Bart is Vice Chairman of the Mibiton Foundation, a government backed foundation that supports the Dutch biotech industry with financing for lab equipment and infrastructure. Furthermore he is member of the task force life sciences of the EVCA. Bart holds a degree in Construction Engineering from Eindhoven Technical University.
